MSB News and Press, Mesabi Trust From 11/04/25

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Drug Administration (FDA) has scheduled a meeting in early December to discuss Mesoblast's data ...

2025-10-30 23:00:00 ET The following segment was excerpted from the Horizon Kinetics Q3 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: 6 Stocks That Offer Undiluted Economic Participation In Resource ...

2025-10-22 09:45:56 ET Thesis Back in January, I said FRMO Corporation ( OTCPK:FRMO ) was a good stock to buy. The company owns a mix of unusual investments, like shares in Horizon Kinetics and some Bitcoin (BTC-USD) mining businesses through Winland and Consensu...

NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first quarter ended September 30, 2025. Mesoblast Chief Executive Dr. Silv...

2025-10-13 08:43:45 ET More on Mesabi Trust Mesabi Trust: Attractive Yield, But Macro Headwinds Loom Dividend scorecard for Mesabi Trust Financial information for Mesabi Trust Read the full article on Seeking Alpha For further details see: Mesabi ...

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9 million on Ryoncil ® (remestemcel-L-rknd) sales for the quarter ended September 30, 202...

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common Procedure Coding System (HCPCS) J-Code assigned to Ryoncil ® (remestemcel-L-rk...

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S. donors in the U.S. and designated as U.S. origin p...

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil ® (remestemcel-L-rknd), the only mesenchymal stromal cell (MSC) prod...

Globus Maritime Limited (GLBS) is expected to report for quarter end 2025-06-30 Cerro Grande Mining Corp (CEGMF) is expected to report for quarter end 2025-06-30 Scinai Immunotherapeutics Ltd. (SCNI) is expected to report for quarter end 2025-06-30 HOOKIPA Pharma Inc. (HOOK) is expect...